Biogen ramps up its SMA rivalry with Novartis with new Spinraza trial
admin 18th September 2019 Uncategorised 0In its latest gambit to preserve market share in spinal muscular atrophy, Biogen’s launching a new Spinraza trial designed to determine whether a higher dose might be more effective than the one already FDA-approved.
More: Biogen ramps up its SMA rivalry with Novartis with new Spinraza trial
Source: fierce